Alvotech begins trading on Nasdaq Stockholm

On Monday, 19 May, Alvotech rang the opening bell at Nasdaq Stockholm to mark the beginning of trading in the company's shares on the Swedish market. The listing is the third for Alvotech, which also trades on Nasdaq in New York and Iceland.

Robert Wessman, Alvotech's founder, CEO and chairman, rang the opening bell and commented: "Alvotech’s goal is to become the global leader in biosimilars development and manufacturing, providing better access to high-quality biologics for patients globally. Today marks another exciting step towards the realization of that vision."

"We think of the listing on Nasdaq Stockholm as a service to our current and future shareholders, providing better access for investors in Nordic and European markets, increasing share liquidity and broadening the shareholder base. I am delighted by the strong interest shown by investors in Sweden, whose sophistication and strength will help to accelerate our growth into a Nordic powerhouse in this important field.” 

Joining the Alvotech team from Iceland were many employees from Alvotech's new R&D operation in Stockholm, formerly part of Xbrane and which Alvotech recently acquired. This operation, on the Karolinska campus, gives Alvotech a significant footprint in one of the largest and most dynamic life sciences ecosystems in the world.

As part of the listing process in Stockholm, Alvotech also announced the completion of a share offering to retail investors in Sweden. The offering brought in nearly $4 million US dollars and gives Alvotech more than three thousand new shareholders in Sweden.

<iframe width="560" height="315" src="https://www.youtube.com/embed/Ttflz3t4UuY?si=otD73IE618VshUES" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>